Mineralys Therapeutics, Inc. MLYS Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -31%+5.9pp | -36.9%+5.2pp | -42.1%+21.1pp | -63.2%-6.9pp | -56.3%+25.9pp | |
| Liquidity | ||||||
| Current ratio | 44.3×+0.6× | 43.8×+18.3× | 25.5×+10.4× | 15.1×-11.4× | 26.5×+12.5× | |
| Per Share | ||||||
| Book value per share | $7.70-19.4% | $9.56+17.1% | $8.17+70.4% | $4.79-25.4% | $6.42+63.1% | |
| Valuation | ||||||
| Market capitalization | $2.23B-22.3% | $2.87B-2.4% | $2.94B+219% | $921.58M-7.6% | $997.24M+62.8% | |
| Price / book | 3.5×-0.9× | 4.4×-0.7× | 5.1×+2.2× | 2.9×0.0× | 2.9×-0.3× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Mineralys Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Mineralys Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.